Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 3/20 | 0.60 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.60 |
| ▸ | PAK4 | O96013 | 2/20 | 0.60 |
| ▸ | PAK3 | O75914 | 2/20 | 0.58 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.58 |
| ▸ | WEE1 | P30291 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 5/20 | 0.51 |
| ▸ | CCND1 | P24385 | 5/20 | 0.51 |
| ▸ | CCND2 | P30279 | 5/20 | 0.51 |
| ▸ | CCND3 | P30281 | 5/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553581 | 0.90 | PAK1 (0.72) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15035083 | 0.90 | WEE1 (0.63) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL14684869 | 0.85 | PAK1 (0.66) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL14684813 | 0.83 | PAK1 (0.62) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL14824762 | 0.79 | PAK1 (0.65) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15030453 | 0.79 | PAK1 (0.79) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15030332 | 0.79 | PAK1 (0.73) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL13554057 | 0.78 | PAK1 (0.76) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15030203 | 0.77 | PAK1 (0.67) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL13553595 | 0.77 | PAK1 (0.81) | PAK1PKN1PAK4PAK3PAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | PAK1 5/4885PKN1 528/4885PAK4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.